# A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

> **NCT05104567** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 138 (actual)

## Conditions studied

- Oesophageal Squamous Cell Carcinoma
- Gastric Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Oesophageal Adenocarcinoma

## Interventions

- **DRUG:** THOR-707
- **DRUG:** Pembrolizumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05104567
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-09
- **Primary completion:** 2023-07-26
- **Final completion:** 2024-09-09
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05104567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05104567, "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05104567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*